Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common Warts

Go back to Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common Warts

Verrica Pharmaceuticals (VRCA) to Resume Trading at 4:30 pm ET

June 26, 2019 4:14 PM EDT

Verrica Pharmaceuticals (NASDAQ: VRCA) to Resume Trading at 4:30 pm ET

... More